19Apr 2024

Preclinical data on antitumor effects of CA102N in pancreatic cancer were presented at the American Association of Cancer Research (“AACR”) Annual Meeting- April 5-10, 2024, San Diego, California.

Dr. Eskouhie Tchaparian presented data on CA102N, the company’s novel pancreatic cancer drug candidate at the 2024 AACR annual meeting. The poster detailed a series of preclinical studies of CA102N activity in pancreatic cancer models. Pancreatic cancer is recognized as a highly aggressive and deadly form of cancer. The five-year survival rate for pancreatic cancer is only 13%; therefore, there is an urgent need for new therapeutic drugs to treat pancreatic cancer and improve the overall survival rate of patients. CA102N primarily inhibits pancreatic cancer cell growth by suppressing the PI3K/Akt/mTOR and Raf/MEK/ERK pathways, inducing apoptosis and inhibiting angiogenesis and cell migration. In in vivo pancreatic cancer models, CA102N demonstrated significant tumor growth inhibition and reduced liver metastasis. Observations of tumor samples from in vivo studies showed that CA102N alters pancreatic cancer stroma by changing its structure and enhances its permeability through the stromal barrier. Compared to current therapeutic drugs, CA102N is expected to overcome treatment limitations imposed by pancreatic tumor stroma. These results provide scientific evidence of CA102N's efficacy in treating pancreatic cancer. The company plans to file for orphan drug approval by the FDA . For more information, please refer to the following link:

13Oct 2023

HSHC(4194.TW) has been granted approval from the US FDA for a Phase 2, randomized, open-label study to evaluate the efficacy, safety, and tolerability of CA102N combined with Trifluridine/Tipiracil (TAS-102) compared to Bevacizumab combined with TAS

CA102N is an innovative investigational anticancer drug designed for the treatment of solid tumors, including colorectal cancer. CA102N is a carrier-mediated drug delivery product with hyaluronic acid (HA) conjugated to Nimesulide. The Hyaluronic Acid – Drug Conjugation (HADC) platform is specifically engineered to target the CD44 receptor overexpressed in solid tumors. HSHC has secured the patent protection of its HADC platform. CA102N is a unique drug that inhibits tumor progression by inducing apoptosis and cell cycle arrest, and inhibiting metastasis and angiogenesis via targeting various signaling pathways such as the AKT pathway (PI3K/AKT/mTOR) pathway and promoting immune response. In addition, due to its direct tumor-targeting property via HA/CD44, an increase in drug accumulation at the target tumor site is observed, in vitro. CA102N, as monotherapy or in combination with LONSURF, was shown to be safe and well-tolerated in subjects with locally advanced or metastatic solid tumors and/or colorectal cancer in a phase I study which implies that the treatment may have potential as part of a combination therapy approach to target cancer more effectively. Further preliminary evidence of anti-tumor activity was also observed in solid tumors, a positive indication that the CA102N treatment might have therapeutic benefits in treating cancer. Exploratory analysis in the dose expansion cohort revealed a favorable median progression-free survival. HSHC is responsible for the ongoing research, development, commercialization, and manufacturing of CA102N.

1 2 3 4